Ovarian cancer in the elderly: Outcomes with neoadjuvant chemotherapy or primary cytoreduction

BackgroundRecent studies have suggested inferior outcomes for elderly women with ovarian cancer. Our goal was to evaluate neoadjuvant chemotherapy versus primary cytoreduction in elderly women.MethodsA retrospective chart review was performed for women aged 65+ diagnosed with ovarian cancer at our institution between 1997 and 2007. Univariate and multivariate logistic regression models were used to evaluate complication rates. Survival was evaluated with Cox regression and the Kaplan–Meier method.ResultsOne hundred seventy-five patients were identified, 34 (19%) of whom were aged 80+. Those aged 65–79 and those 80+ received neoadjuvant chemotherapy with equal frequency (19% vs. 21%, p = 0.92). Treatment with neoadjuvant chemotherapy was associated with odds ratios of 0.80 (95% CI 0.37–1.75) for surgical complications and 0.79 (95% CI 0.33–1.90) for chemotherapeutic complications. In those aged 80+, the frequency of surgical complications (OR 1.01, p = 0.62) and chemotherapeutic complications (OR 1.04, p = 0.78) did not differ compared to younger patients. Overall survival did not differ based on initial treatment regimen, with 34 months in the primary surgery group and 29 months in the neoadjuvant chemotherapy group (p = 0.65). The median disease specific survival for those aged 65–79 was 35 months, and 24 months in those aged 80+ (p = 0.15). Post-operative mortality for patients aged 80+ was zero.ConclusionsIn our patient population, those aged 80+ have similar surgical and chemotherapy-related complication rates and comparable survival to those aged 65–79. The choice of initial treatment modality does not appear to impact survival when the decision is made in a selective fashion.